Erbitux Opportunity In Japan Has Been Overlooked By Investors
This article was originally published in PharmAsia News
ImClone said July 16 that its oncologic Erbitux (cetuximab) has been approved in Japan for treatment of advanced colon cancer. Under an existing deal, Merck KGaA will receive 50 percent of profits from sales in Japan, and ImClone and Bristol-Myers Squibb will receive 25 percent each. An application for Erbitux in earlier-stage colon cancer is pending with Japanese regulators. Several analysts say that the Japanese market is an opportunity for Erbitux that has been overlooked by investors. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.